Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Neoplasm Metastasis 1Melanoma 1

Interventions

Melphalan 3tebentafusp 1sargramostim 1fotemustine 1aflibercept 1Ranibizumab 1Nivolumab 1Neoadjuvant Therapy 1Melatonin 1MART-1 Antigen 1Ipilimumab 1Eye Enucleation 1Dacarbazine 1Colony-Stimulating Factors 1Chemotherapy, Cancer, Regional Perfusion 1Brachytherapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uveal Melanoma × Chemotherapy, Cancer, Regional Perfusion × Clear all
NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Delcath Systems Inc.

Phase 3 Completed
93 enrolled
Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡